Kind Pharmaceuticals LLC
11
5
5
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
0%
0 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study of AND017 to Evaluate Efficacy and Safety in Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Patients With Anemia
Role: lead
A Study of AND017 to Evaluate Efficacy and Safety in Patients With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD)
Role: lead
A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer
Role: lead
A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome
Role: lead
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
Role: lead
A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy
Role: lead
A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Role: lead
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
Role: lead
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
Role: lead
A Food-Effect Study of AND017 in Healthy Participants
Role: lead
A Dose-escalation Study of AND017 in Healthy Subjects
Role: lead
All 11 trials loaded